What a week. We saw a flurry of new policies as major health organizations scramble to get ahead of AI’s rapid integration into research. Meanwhile, some high-profile clinical trial results sent ripples through the market, and a landmark NIH study just changed what we thought we knew about a common skin cancer.
-
Vertex Halts Non-Opioid Pain Drug After Phase 2 Failure
In a major setback, Vertex Pharmaceuticals announced its investigational non-opioid pain drug, VX-993, failed to meet its primary endpoint in a Phase 2 trial. The study, which evaluated patients after bunionectomy surgery, showed the drug was not statistically better than placebo at reducing acute pain. As a result, Vertex will not be moving VX-993 forward into pivotal development for acute pain, a disappointing outcome for a high-profile program.
Published: August 4, 2025
https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-vx-993-treatment-acute -
NIH Study Reveals Virus Can Directly Cause Skin Cancer
A groundbreaking case study from the NIH has overturned a long-held belief about the cause of cutaneous squamous cell carcinoma (cSCC). Researchers found that in an immunocompromised patient, a common beta-HPV strain—previously thought to be benign—had integrated into the tumor’s DNA and was directly driving the cancer’s growth. This discovery, published in the New England Journal of Medicine, suggests that for individuals with weakened immune systems, the virus itself can be a direct carcinogen, opening up new avenues for research and treatment.
Published: July 30, 2025
Beta-HPV can directly cause skin cancer in immunocompromised people | National Institutes of Health (NIH) -
CMS Urged to Launch National Deprescribing Model
A new article in Health Affairs is making a strong case for CMS to launch a national deprescribing model by 2026. The proposal aims to reduce medication-related harm and costs for older adults by creating a structured, pharmacist-led process to safely discontinue potentially inappropriate medications. With over a third of older adults on at least one such drug, the model could prevent falls and cognitive impairment while generating significant Medicare savings.
Published: August 4, 2025
https://www.healthaffairs.org/do/10.1377/forefront.20250801.588301/full/ -
FDA Grants Fast Track to Novel Stem-Cell Virus Therapy for Sarcoma
The FDA has granted Fast Track designation to Calidi Biotherapeutics’ CLD-201 (SuperNova), a first-in-class therapy for soft tissue sarcoma. The treatment uses an innovative approach where an oncolytic virus is loaded onto allogeneic stem cells. This designation underscores the significant unmet need for patients with sarcoma and aims to accelerate the development and review of this promising new treatment.
Published: August 1, 2025
Oncology Drugs Fast-Tracked by the FDA in July 2025
Tools & Tips
-
AI-Powered Trial Tech
Curious about the new wave of AI-driven clinical trial software? A 2025 trend report breaks down how AI is being used for everything from protocol design and recruitment to real-time safety monitoring. It’s a great read to get up to speed on the tools shaping the future of our work.
Clinical Trial Technology Trends: 7 Powerful Positive Changes 2025 -
Next-Gen CTMS
If you’re involved in selecting or managing clinical trial systems, a 2025 comparison guide provides a solid overview of the major players like Medidata, Veeva, and CRIO, detailing their strengths for different types of research organizations.
6 Best Clinical Trial Management Software (CTMS) Solutions for 2025
Fun Fact
Did you know? The first recorded “clinical trial” appears in the Book of Daniel! King Nebuchadnezzar ordered his subjects to eat only meat and wine, but a few rebels opted for vegetables and water. After 10 days, the vegetarian group appeared healthier, and the king let them continue their diet—an early, if uncontrolled, human experiment guiding a public health decision.
We’d love to hear from you!
Have you participated in any clinical research events or utilized new clinical research tools recently? Share your experiences or insights with us—we’re featuring selected community voices in next week’s edition.